CollPlant Biotechnologies (XTAE:CLGN) 3-Year Revenue Growth Rate : 2.60% (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is CollPlant Biotechnologies 3-Year Revenue Growth Rate?

CollPlant Biotechnologies's Revenue per Share for the three months ended in Dec. 2023 was ₪0.01.

During the past 12 months, CollPlant Biotechnologies's average Revenue per Share Growth Rate was 3463.00% per year. During the past 3 years, the average Revenue per Share Growth Rate was 2.60% per year. During the past 5 years, the average Revenue per Share Growth Rate was -22.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 12 years, the highest 3-Year average Revenue per Share Growth Rate of CollPlant Biotechnologies was 674.70% per year. The lowest was -61.30% per year. And the median was 4.60% per year.

Competitive Comparison of CollPlant Biotechnologies's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, CollPlant Biotechnologies's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CollPlant Biotechnologies's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CollPlant Biotechnologies's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where CollPlant Biotechnologies's 3-Year Revenue Growth Rate falls into.

CollPlant Biotechnologies 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

CollPlant Biotechnologies (XTAE:CLGN) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

CollPlant Biotechnologies 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of CollPlant Biotechnologies's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

CollPlant Biotechnologies (XTAE:CLGN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CollPlant Biotechnologies Ltd (XTAE:CLGN) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

CLGN:USA CPT:Germany

Address

4 Oppenheimer Street, P.O. Box 4132, Weizmann Science Park, Rehovot, ISR, 7670104

Website

https://www.collplant.com

CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The company's revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing.